Quantbot Technologies LP Has $13.53 Million Stake in Thermo Fisher Scientific Inc. $TMO

Key Points

• Quantbot Technologies LP increased its holdings in Thermo Fisher Scientific by 42.4%, owning 27,188 shares valued at approximately $13.5 million after acquiring an additional 8,096 shares.
• In the first quarter, other institutional investors such as Wellington Management and Korea Investment CORP also boosted their stakes in Thermo Fisher Scientific, indicating a strong interest in the stock among hedge funds.
• Thermo Fisher Scientific reported $5.36 EPS for the last quarter, surpassing analysts' expectations, alongside a 2.9% increase in year-over-year revenue.

Quantbot Technologies LP increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 42.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 27,188 shares of the medical research company's stock after purchasing an additional 8,096 shares during the period. Thermo Fisher Scientific makes up 0.4% of Quantbot Technologies LP's holdings, making the stock its 28th largest position. Quantbot Technologies LP's holdings in Thermo Fisher Scientific were worth $13,529,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. raised its stake in shares of Thermo Fisher Scientific by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 33,479,957 shares of the medical research company's stock valued at $16,659,627,000 after purchasing an additional 230,382 shares during the period. Northern Trust Corp raised its stake in shares of Thermo Fisher Scientific by 13.2% in the 4th quarter. Northern Trust Corp now owns 3,910,015 shares of the medical research company's stock valued at $2,034,107,000 after purchasing an additional 455,004 shares during the period. T. Rowe Price Investment Management Inc. raised its stake in shares of Thermo Fisher Scientific by 86.9% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,083,900 shares of the medical research company's stock valued at $1,604,338,000 after purchasing an additional 1,433,444 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Thermo Fisher Scientific by 4.1% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,925,591 shares of the medical research company's stock valued at $1,455,774,000 after purchasing an additional 115,463 shares during the period. Finally, Pictet Asset Management Holding SA raised its stake in shares of Thermo Fisher Scientific by 7.2% in the 1st quarter. Pictet Asset Management Holding SA now owns 2,879,274 shares of the medical research company's stock valued at $1,432,816,000 after purchasing an additional 193,378 shares during the period. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Performance

TMO stock traded down $11.3820 during mid-day trading on Thursday, hitting $483.4280. 1,360,628 shares of the company were exchanged, compared to its average volume of 2,488,796. The business has a 50 day simple moving average of $439.69 and a 200-day simple moving average of $458.78. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $182.55 billion, a PE ratio of 27.96, a price-to-earnings-growth ratio of 2.66 and a beta of 0.74. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. The firm had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business's revenue for the quarter was up 2.9% compared to the same quarter last year. During the same period last year, the business posted $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.95%.

Insider Activity at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 295 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $500.04, for a total value of $147,511.80. Following the completion of the sale, the chief executive officer directly owned 115,174 shares in the company, valued at approximately $57,591,606.96. The trade was a 0.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the sale, the executive vice president owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 18,896 shares of company stock valued at $8,593,838 over the last 90 days. Company insiders own 0.33% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Wall Street Zen cut Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a report on Sunday, August 10th. HSBC restated a "hold" rating and issued a $510.00 price objective on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. The Goldman Sachs Group set a $610.00 price objective on Thermo Fisher Scientific and gave the company a "buy" rating in a report on Wednesday, April 23rd. Scotiabank upgraded Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price objective for the company in a report on Friday, July 11th. Finally, Royal Bank Of Canada decreased their price objective on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Sixteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $593.00.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.